In ovarian cancer, studies on EpCAM overexpression in tumor tissue and survival gave contradictory results [18,19,20]—possibly because of the use of different anti-EpCAM antibodies, heterogeneous histological subtypes of epithelial ovarian tumors analyzed, and also different immunohistochemistry scoring methods [29]. This evidence concerns the gene EPCAM and neoplasm.